Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJQG82)

• Drug Name: M&B 28767 Drug Info
• Synonyms: M&B-28767; Dpt-prostaglandin E1

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5311223
  CAS Number: CAS 80558-61-8
  TTD Drug ID: DMJQG82

Molecule-Related Drug Atlas

Drug(s) Targeting Prostaglandin E2 receptor EP1 (PTGER1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AS-013	DMD7XWS	Thrombosis	DB61-GB90	Phase 3	[5]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[3]
BUTAPROST	DMVYNJZ	Discovery agent	N.A.	Patented	[6]
ZD6416	DM46JIR	Pain	MG30-MG3Z	Discontinued in Phase 2	[7]
ONO-8130	DMBDCL4	Pollakiuria	MF50.1	Terminated	[8]
ONO-8711	DM2VRK7	Pain	MG30-MG3Z	Terminated	[9]
U46619	DM13FX4	Discovery agent	N.A.	Investigative	[3]
carbacyclin	DMMBQYE	Discovery agent	N.A.	Investigative	[4]
PGD2	DMYDW6J	Discovery agent	N.A.	Investigative	[10]
cicaprost	DM7ZJ4H	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting Prostaglandin E2 receptor EP4 (PTGER4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[2]
RQ-00000007 (oral)	DMMYTRU	Pain	MG30-MG3Z	Phase 2	[11]
ONO-AE1-437	DMCUGI8	Asthma	CA23	Phase 2	[12]
BGC-20-1531	DMS2MQ5	Migraine	8A80	Phase 2	[13]
IK-007	DMBLFPN	Non-small-cell lung cancer	2C25	Phase 1/2	[14]
TPST-1495	DM3GSB2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
E7046	DMFVT43	Rectal adenocarcinoma	2B92	Phase 1	[16]
ONO-4232	DMO4SD2	Acute heart failure	BD10-BD13	Phase 1	[17]
ONO-4578	DME63VK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
AN0025	DMGSYPY	Aggressive cancer	2A00-2F9Z	Phase 1	[18]

Drug(s) Targeting Prostaglandin E2 receptor EP2 (PTGER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[6]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[19]
Alprostadil	DMWH7NQ	Aorta coarctation		Approved	[20]
Iloprost	DMVPZBE	Pulmonary arterial hypertension	BB01.0	Approved	[21]
Omidenepag isopropyl	DMUX7Z8	Glaucoma/ocular hypertension	9C61	Approved	[22]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[23]
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[2]
CP-533536	DMZEJLB	Osteoporosis	FB83.0	Phase 2	[24]
Taprenepag	DM1TSHL	Glaucoma/ocular hypertension	9C61	Phase 2	[25]
TPST-1495	DM3GSB2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]

Drug(s) Targeting Prostaglandin F2-alpha receptor (PTGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[6]
Latanoprost	DMI5OXG	Ocular hypertension	9C61.01	Approved	[26]
BOL-303259-X	DM2EXC5	Open-angle glaucoma	9C61	Approved	[27]
Tafluprost	DMFC41K	Glaucoma/ocular hypertension	9C61	Approved	[28]
Carboprost Tromethamine	DMS3508	Abortion	JA00	Approved	[29]
Travoprost	DM20K91	Ocular hypertension	9C61.01	Approved	[30]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[23]
PGF2ALPHA-IE	DM5DAP3	Glaucoma/ocular hypertension	9C61	Phase 3	[31]
ONO-9054	DM5O6GC	Glaucoma/ocular hypertension	9C61	Phase 2	[32]
PDC-41	DM74YO8	Dysmenorrhea	GA34.3	Phase 1	[33]

Drug(s) Targeting Thromboxane A2 receptor (TBXA2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alprostadil	DMWH7NQ	Aorta coarctation		Approved	[34]
Ridogrel	DMWH9CN	Acute myocardial infarction	BA41	Approved	[35]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[23]
Ramatroban	DMB8UQ3	Perennial allergic rhinitis	CA08.03	Phase 2/3	[36]
KP-496	DMCO8UZ	Asthma	CA23	Phase 2	[37]
FK-070	DMJSD5W	Angina pectoris	BA40	Phase 2	[38]
TAK-128	DMHPEFS	Diabetic neuropathy	8C0Z	Phase 2	[39]
Ifetroban sodium	DMZP84Y	Thrombosis	DB61-GB90	Phase 2	[40]
Ifetroban	DMEV39E	Aspirin-induced asthma	CA23.20	Phase 2	[41]
YM-57158	DMS31YW	Allergic rhinitis	CA08.0	Phase 1	[42]

Drug(s) Targeting Prostaglandin E2 receptor EP3 (PTGER3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[2]
ONO-9054	DM5O6GC	Glaucoma/ocular hypertension	9C61	Phase 2	[32]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[2]
BUTAPROST	DMVYNJZ	Discovery agent	N.A.	Patented	[6]
DG041	DMVO9WM	Peripheral vascular disease	BD4Z	Discontinued in Phase 2	[43]
GR-63799X	DM13GK8	Asthma	CA23	Discontinued in Phase 1	[44]
U46619	DM13FX4	Discovery agent	N.A.	Investigative	[4]
carbacyclin	DMMBQYE	Discovery agent	N.A.	Investigative	[2]
PGD2	DMYDW6J	Discovery agent	N.A.	Investigative	[3]
butaprost (free acid form)	DM5MZHP	Discovery agent	N.A.	Investigative	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin E2 receptor EP1 (PTGER1)	TTG1QMU	PE2R1_HUMAN	Agonist	[2]
Prostaglandin E2 receptor EP2 (PTGER2)	TT1ZAVI	PE2R2_HUMAN	Agonist	[3]
Prostaglandin E2 receptor EP3 (PTGER3)	TTPNGDE	PE2R3_HUMAN	Agonist	[2]
Prostaglandin E2 receptor EP4 (PTGER4)	TT79WV3	PE2R4_HUMAN	Agonist	[2]
Prostaglandin F2-alpha receptor (PTGFR)	TTT2ZAR	PF2R_HUMAN	Agonist	[2]
Thromboxane A2 receptor (TBXA2R)	TT2O84V	TA2R_HUMAN	Agonist	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1913).
• [2] Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
• [3] Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
• [4] The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
• [5] Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7.
• [6] Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
• [7] The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology. 2003 Jan;124(1):18-25.
• [8] ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. Pain. 2011 Jun;152(6):1373-81.
• [9] Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis. 2001 Dec;22(12):2001-4.
• [10] Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47.
• [11] Clinical pipeline report, company report or official report of Avarx.
• [12] An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90.
• [13] BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327.
• [14] Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2015 Dec 21;2(1):3-9.
• [15] Clinical pipeline report, company report or official report of Tempest Therapeutics.
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345.
• [18] AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiother Oncol. 2023 Aug;185:109669.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
• [20] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [21] Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
• [22] Clinical pipeline report, company report or official report of Santen Pharmaceutical.
• [23] Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
• [24] Pfizer. Product Development Pipeline. March 31 2009.
• [25] A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
• [26] PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70.
• [27] Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5.
• [28] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [29] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [30] Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8.
• [31] Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7.
• [32] IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
• [33] THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97.
• [34] Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6.
• [35] Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42.
• [36] Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats. Int Immunopharmacol. 2007 Nov;7(11):1483-7.
• [37] Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
• [38] Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
• [39] ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.
• [40] AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.
• [41] Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev. 2001 Summer;19(2):97-115.
• [42] In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
• [43] BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
• [44] Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 1999 Feb;126(4):849-58.